Results 51 to 60 of about 27,110 (205)

Elevated troponin in hematopoietic stem cell transplantation-associated thrombotic microangiopathy: A case report

Thrombosis Update, 2020
Elevated troponin was associated with poor prognosis during thrombotic microangiopathy (TMA) in several reports, but elevated troponin in haploidentical hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TATMA) has not yet ...
Lili Zhou, Ying Wang, Fei Zhou, Xiao Ma, Xuefeng He, MD, PhD   +4 more
doaj   +1 more source

The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: Clinical significance and comparison with cyclosporine [PDF]

, 1993
The histopathological changes in 51 renal allograft biopsies from patients immunosuppressed with FK506 were compared with those seen in 30 needle biopsies obtained from patients on cyclosporine.
Demetris, AJ, Jordan, ML, Randhawa, PS, Shapiro, R, Starzl, TE   +4 more
core   +1 more source

Dasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report

SAGE Open Medical Case Reports
Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase ...
Ryan Sabour, Sohrab Kharabaf, Eric Frazier, Matthew Nguyen, Dao Le, Jonathan Zuckerman, Ramy Hanna   +6 more
doaj   +1 more source

COVID-19 Microangiopathy: Insights into plasma exchange as a therapeutic strategy

Hematology, Transfusion and Cell Therapy
COVID-19-associated thrombotic microangiopathy has emerged as a severe complication that exacerbates morbidity and mortality in critical cases. Thrombotic microangiopathy, characterized by microvascular thrombosis and endothelial injury, includes ...
Yigit Baykara, Kaan Sevgi, Yamac Akgun
doaj   +1 more source

Thrombotic Microangiopathy Complicating Cyclosporine in Renal Transplant Patients

Advanced Medical Journal, 2023
Background and objectives: Experience with cyclosporine associated thrombotic microangiopathy in renal allograft recipients is generally anecdotal; detailed descriptions of clinical behavior, therapeutic options and experience are also anecdotal and few.
Safa Al-Mukhtar
doaj   +1 more source

Risk factors for silent cerebral infarction in immune‐mediated thrombotic thrombocytopenic survivors

British Journal of Haematology, EarlyView.
Summary Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) survivors are predisposed to silent cerebral infarctions (SCI) defined as radiological evidence of brain ischaemia without focal symptoms. This study examined risk factors associated with SCI burden in iTTP survivors during remission.
Binish Javed, Jia Yu, Jenna Brown, Jay Meade, Gloria F. Gerber, Michael B. Streiff, Peggy Kraus, Samuel Merrill, Allyson M. Pishko, Jennifer Yui, Rakhi P. Naik, Robert A. Brodsky, Doris D. Lin, Shruti Chaturvedi   +13 more
wiley   +1 more source

Prognostic factors in thrombotic thrombocytopenic purpura

Türk Biyokimya Dergisi, 2022
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy with no standardized prognostic model to predict mortality. The aim of the study is to determine parameters associated with TTP-related mortality.
Yalçıner Merih, İlhan Osman
doaj   +1 more source

COVID-19 and thrombotic microangiopathy

Акушерство, гинекология и репродукция, 2022
As shown by numerous studies conducted during the pandemic, the severe course of COVID-19 is accompanied by multiple organ failure. Cytokine storm, hypercoagulation, complement hyperactivation and other arms comprise the overall picture of the ...
E. V. Sluhanchuk, V. O. Bitsadze, J. Kh. Khizroeva, M. V. Tretyakova, A. S. Shkoda, O. P. Artyukov, V. I. Tsibizova, A. L. Mishchenko, K. N. Grigorieva, J.-С. Gris, E. Elalamy, A. D. Makatsariya   +11 more
doaj   +1 more source

Safety and efficacy of eculizumab in adult and pediatric patients with aHUS, with or without baseline dialysis [PDF]

, 2015
C
Hourmant, Maryvonne, Kincaid, John F, Legendre, Christophe M, Menne, Jan, van de Kar, Nicole CAJ, Vande Walle, Johan   +5 more
core   +1 more source

Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study

Haemophilia, EarlyView.
ABSTRACT Background The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting for activated factor (F)VIII in people with haemophilia A (HA).
Tyler W. Buckner, Shannon L. Carpenter, Nabil Daoud, Christine L. Kempton, Lucy Lee, Lynn Malec, Thomas W. McLean, Paul Morton, Carrie O'Neill, Janice M. Staber, Michael Wang, Stacy E. Croteau, Michael Recht   +12 more
wiley   +1 more source